| abstract |
The invention relates to the use of NKG2D receptor/NKG2D ligand interaction blockers for producing a medicament for treating auto-immune diseases, especially multiple sclerosis, and for blocking the NKG2D receptor, said blockers being selected from the group containing soluble NKG2D receptors, soluble MICA, soluble MICB, soluble ULBP1, soluble ULBP2, soluble ULBP3, soluble ULBP4, soluble RAET1L, soluble RAET1G, and allelic variants or fragments or derivatives of said blockers. The invention also relates to synthetically produced NKG2D receptor/NKG2D ligand interaction blockers. |